Zydus Lifesciences launched ANVIMO, an affordable breakthrough treatment for Cytomegalovirus (CMV) infection in transplant patients on March 5, 2025, significantly reducing costs by 91%. ANVIMO ensures better safety and effectiveness compared to existing treatments, improving access to life-saving care for Indian patients.